Wockhardt

Stocks to Watch, June 2: L&T, Anant Raj, Ola Electric, Paytm, Alkem Labs among shares to remain on investors' and traders' radar today

Novel antibiotic to be launched in India around the same time; company to commercialise product on its own in US

Wockhardt recently received USFDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections, including pyelonephritis, in adults.

The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime

Mayank Jain, market analyst at Share.Market by PhonePe believes that the long-term trend for Ola Electric can change from 'Bearish to Bullish' if the stock manages to sustain above ₹40 consistently.

Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Wockhardt, TFCI, and HBL Engineering today

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

In the March quarter (Q4FY26), Wockhardt posted net profit year-on-year (Y-o-Y) of ₹166 crore, as compared to a net loss of ₹25 crore a year ago

The Indian equity market was trading sharply higher, driven by hopes of de-escalation in the war between US-Israel and Iran

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'

Ten out of Nifty 500 stocks declined up to 23% in October even as the Nifty and Nifty 500 gained around 4.5% each; should you buy these stocks or sell? Here's what the technical charts suggest.

Drug firm Wockhardt on Wednesday said it has submitted a new drug application for its novel antibacterial drug with the US health regulator. The company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (USFDA) for its novel antibacterial agent Zidebactam-Cefepime injection, the Mumbai-based drugmaker said in a regulatory filing. The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria, including multidrug-resistant (MDR), it added. In the US and EU, more than 8 million cases of cUTI are reported every year, reflecting the global burden of Gram-negative infections, the drug firm stated. "This milestone marks the first-ever NDA submission to the US FDA for a drug, fully discovered and developed by an Indian pharmaceutical company, a momentous achievement for Indian innovation," Wockhardt Ltd said. The NDA submission follows

Thus far in the calendar year 2025, the BSE smallcap index has underperformed the market by falling 5%, as against 3% decline in midcap index and 3% rise in the BSE Sensex.

Shukra Pharmaceuticals on Wednesday said it has entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd. The authorization is effective from September 9, 2025 and is valid until March 2026, an exchange filing said. The products include advanced anti-infective formulations and antibiotics developed to combat critical infections. The mandate includes distribution and management of products across all ESIC/ESIS hospitals and Defence/AFMSD/DGAFMS units throughout India, the filing said. "This collaboration further strengthens Shukra Pharmaceuticals presence in institutional and government healthcare networks across India, enhancing revenue visibility and operational footprint," the company said. Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products as well as laboratory testing.

Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

The decision follows years of financial losses in the US generics business, including loss of nearly $8 million in FY 2025, Wockhardt said in a BSE filing

Shares of Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17% on the BSE in Wednesday's intra-day trade surpassed its previous high of ₹1,678.60 touched on February 6, 2025.

Company to launch Zaynich in India this fiscal; sees $7 bn market in US and EU and ₹17,000 crore in India; USFDA, EU filings underway for FY26

Drug firm Wockhardt on Thursday reported a consolidated net loss of Rs 45 crore in the fourth quarter ended March 31, 2025. The drug maker had reported a net loss of Rs 177 crore in the January-March quarter of FY24. Revenue from operations rose to Rs 743 crore in the fourth quarter as compared to Rs 700 crore in the year-ago period, Wockhardt said in a regulatory filing. For FY25, the company said its net loss stood at Rs 57 crore as compared to Rs 472 crore in the year-ago period. Revenue increased to Rs 3,012 crore as compared to Rs 2,798 crore in 2023-24 fiscal. Shares of the company closed at Rs 1,347.75 apiece, 0.63 per cent higher from previous close, on the BSE.